Gábor Mikala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gábor Mikala has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Gergely Varga
Department of Internal Medicine and Haematology, Semmelweis University, 1085 Budapest, Hungary
2 shared publications - Hussain Alizadeh
Division of Hematology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary
2 shared publications - László Váróczy
Department of Hematology, Institute for Medicine, Clinical Center, University of Debrecen, 4032 Debrecen, Hungary
2 shared publications - Márk Plander
Markusovszky University Teaching Hospital, 9700 Szombathely, Hungary
2 shared publications - Szabolcs Kosztolányi
1st Department of Internal Medicine, University of Pécs, 7624 Pécs, Hungary
2 shared publications - Tamas Masszi
Department of Internal Medicine and Haematology, Semmelweis University, 1085 Budapest, Hungary
2 shared publications
Latest Publications
- Open Access
Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis
Background/Objectives: Dexamethasone has long served as the cornerstone of therapy for multiple myeloma; however, its optimal dosing remains ill-defined, particularly when balanced against its profound toxicity profile. Recent therapeutic advances have consequently intensified interest in steroid dose-reduction strategies. This retrospective, multicenter study aimed to evaluate the impact of varied dexamethasone dosing regimens on clinical outcomes within a real-world setting. Methods: We conducted a retrospective multicenter study across 11 Hungarian centers, enrolling 272 patients with multiple myeloma who received lenalidomide–dexamethasone therapy. Treating physicians determined dosing strategies at their discretion for each patient. We retrospectively stratified patients into three cohorts based on their prescribed weekly dexamethasone dose: 40 mg, 20 mg, and less than 20 mg. Results: We observed a distinct interaction between patient age and weekly dexamethasone dose. Nonetheless, we detected no statistically significant difference in progression-free survival (PFS) among the three dosing cohorts (p = 0.632). Similarly, dexamethasone dose intensity demonstrated no significant association with overall treatment response (p = 0.560). Subgroup analysis restricted to patients with high-risk cytogenetics also showed no significant disparities in PFS (p = 0.312). Furthermore, early treatment response rates at 2 and 6 months were also independent of the dexamethasone dose. Notably, grade 3–5 adverse events were numerically more frequent in the 40 mg group. The lack of significant differences in these outcome measures is particularly important, given the baseline age imbalances among the cohorts. Conclusions: Lower initial dexamethasone dose was not associated with statistically significant differences in progression-free survival or treatment response in this retrospective cohort. Although Grade 3–5 adverse events were numerically more frequent in the 40 mg group, these observations warrant further investigation in prospective studies.
Open AccessLower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis
Background/Objectives: Dexamethasone has long served as the cornerstone of therapy for multiple myeloma; however, its optimal dosing remains ill-defined, particularly when balanced against its profound toxicity profile. Recent therapeutic advances have consequently intensified interest in steroid dose-reduction strategies. This retrospective, multicenter study aimed to evaluate the impact of varied dexamethasone dosing regimens on clinical outcomes within a real-world setting. Methods: We conducted a retrospective multicenter study across 11 Hungarian centers, enrolling 272 patients with multiple myeloma who received lenalidomide–dexamethasone therapy. Treating physicians determined dosing strategies at their discretion for each patient. We retrospectively stratified patients into three cohorts based on their prescribed weekly dexamethasone dose: 40 mg, 20 mg, and less than 20 mg. Results: We observed a distinct interaction between patient age and weekly dexamethasone dose. Nonetheless, we detected no statistically significant difference in progression-free survival (PFS) among the three dosing cohorts (p = 0.632). Similarly, dexamethasone dose intensity demonstrated no significant association with overall treatment response (p = 0.560). Subgroup analysis restricted to patients with high-risk cytogenetics also showed no significant disparities in PFS (p = 0.312). Furthermore, early treatment response rates at 2 and 6 months were also independent of the dexamethasone dose. Notably, grade 3–5 adverse events were numerically more frequent in the 40 mg group. The lack of significant differences in these outcome measures is particularly important, given the baseline age imbalances among the cohorts. Conclusions: Lower initial dexamethasone dose was not associated with statistically significant differences in progression-free survival or treatment response in this retrospective cohort. Although Grade 3–5 adverse events were numerically more frequent in the 40 mg group, these observations warrant further investigation in prospective studies.
- Open Access
- 30 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 286
Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis
Background/Objectives: Despite therapeutic advances, managing relapsed/refractory multiple myeloma (RRMM) remains challenging. For patients with frailty, comorbidities, mobility limitations, or when treatment preference and drug accessibility are key considerations, the all-oral ixazomib–lenalidomide–dexamethasone (IRd) regimen offers a practical alternative. Methods: We performed a multicenter retrospective study of RRMM patients treated with IRd in Hungary between 1 January 2020 and 30 June 2025. Results: The median age at treatment initiation was 73.7 years. Treatment was initiated for clinical progression in 38.2%, biochemical progression in 53.3%, and for intolerance or toxicity of prior therapy in 8.6%. Median progression-free survival (PFS) was 18.7 months, and median overall survival (OS) was 34.7 months. Patients treated at biochemical progression had significantly longer PFS than those treated at clinical progression (24.3 vs. 15.6 months; p = 0.004), with additional benefit when IRd was initiated owing to intolerance or toxicity of previous therapy (p = 0.04). In the second-line setting, median PFS was 24.5 months, and median OS was not reached. Adverse events occurred in 68.3% of patients; dose reductions were required in 18.4%, and 21.6% discontinued treatment because of intolerance or toxicity. Most common toxicities were neutropenia (32.9%), thrombocytopenia (27.6%), diarrhoea (25%), peripheral neuropathy (25.3%), and infections (22.4%). Conclusions: IRd initiation at biochemical progression was associated with superior PFS compared with treatment at clinical progression. When compared with a recent Hungarian multicenter cohort treated with second-line daratumumab, lenalidomide, and dexamethasone, outcomes with IRd are not significantly inferior (36-month OS calculated from 2nd line treatment initiation: 65.5% for DRd vs. 60% in our cohort; p = 0.56). These real-world data support IRd as an effective, convenient, all-oral option for appropriately selected RRMM patients.
- 30 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (1) , 286
Open AccessIxazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis
Background/Objectives: Despite therapeutic advances, managing relapsed/refractory multiple myeloma (RRMM) remains challenging. For patients with frailty, comorbidities, mobility limitations, or when treatment preference and drug accessibility are key considerations, the all-oral ixazomib–lenalidomide–dexamethasone (IRd) regimen offers a practical alternative. Methods: We performed a multicenter retrospective study of RRMM patients treated with IRd in Hungary between 1 January 2020 and 30 June 2025. Results: The median age at treatment initiation was 73.7 years. Treatment was initiated for clinical progression in 38.2%, biochemical progression in 53.3%, and for intolerance or toxicity of prior therapy in 8.6%. Median progression-free survival (PFS) was 18.7 months, and median overall survival (OS) was 34.7 months. Patients treated at biochemical progression had significantly longer PFS than those treated at clinical progression (24.3 vs. 15.6 months; p = 0.004), with additional benefit when IRd was initiated owing to intolerance or toxicity of previous therapy (p = 0.04). In the second-line setting, median PFS was 24.5 months, and median OS was not reached. Adverse events occurred in 68.3% of patients; dose reductions were required in 18.4%, and 21.6% discontinued treatment because of intolerance or toxicity. Most common toxicities were neutropenia (32.9%), thrombocytopenia (27.6%), diarrhoea (25%), peripheral neuropathy (25.3%), and infections (22.4%). Conclusions: IRd initiation at biochemical progression was associated with superior PFS compared with treatment at clinical progression. When compared with a recent Hungarian multicenter cohort treated with second-line daratumumab, lenalidomide, and dexamethasone, outcomes with IRd are not significantly inferior (36-month OS calculated from 2nd line treatment initiation: 65.5% for DRd vs. 60% in our cohort; p = 0.56). These real-world data support IRd as an effective, convenient, all-oral option for appropriately selected RRMM patients.